Condition
Overweight
Obesity
Locations
United States
Start date
12/08/2026
Identifiers
Trial ID NN9060-8607,
NCT number NCT07767175,
Eudract number Not Available
NCT number NCT07767175,
Eudract number Not Available
Summary
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Trial Overview:
Treatment
DRUG: NNC0721-8060
DRUG: Semaglutide
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Aug 12 2026 - Sep 23 2027
Participants
142
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 55 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.